# Patrick Heron

> Patrick Heron is a Series A investor at Frazier Healthcare Partners backing Biotechnology. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures)
- Location: Menlo Park, United States
- Total investments: 16
- Last investment: Oct 2025
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/patrick-heron-b4b72913/

Patrick Heron is a Series A investor at Frazier Healthcare Partners in Menlo Park focused on Biotechnology and Therapeutics. Patrick Heron is the Board Director at VentiRX Pharmaceuticals.Mr. Heron became a General Partner with the onset of FH V (2005), having been a partner in Frazier Healthcare IV (2001). Mr. Heron focuses on biotechnology and growth equity opportunities. Mr. Heron joined Frazier Healthcare in 1999 and founded QuatRx Pharmaceuticals, anin-licensor of early-stage clinical development compounds, with its core management team in late 2000. He also led the opening of Frazier Healthcare's Palo Alto office in the summer of 2003. Mr. Heron currently serves on the boards of Avera Pharmaceuticals, Cerexa, Chimerix, Informed Medical Communications, Panomics, QuatRx Pharmaceuticals and Trubion Pharmaceuticals.Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice after starting his career working with large pharmaceutical clients on the East Coast. His projects included corporate strategy, M&A, product launch, sales force optimization, corporate partnering and research prioritization. Prior to joining McKinsey, Mr. Heron also worked with Massachusetts General Hospital in evaluating spin-off opportunities and with Cetus Corporation. He was a Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 75% |
| Therapeutics | 8 | 50% |
| Health Care | 7 | 44% |
| Pharmaceutical | 5 | 31% |
| Medical | 3 | 19% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 38% |
| Series B | 4 | 25% |
| Series C | 2 | 13% |
| Funding Round | 2 | 13% |
| Series F | 1 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 56% |
| China | 1 | 6% |
| Canada | 1 | 6% |
| Germany | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tubulis | Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M | Series C | Oct 15, 2025 |  |
| Alpha-9 Oncology | Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M | Series C | Oct 23, 2024 |  |
| Alpha-9 Oncology | Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $75M | Series B | Dec 14, 2022 |  |
| MBX Biosciences | MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. | $115M | Series B | Nov 14, 2022 |  |
| SanReno Therapeutics | SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China. | $40M |  | Nov 30, 2021 |  |
| HilleVax | HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts. | $135M | Venture - Series Unknown | Sep 08, 2021 |  |
| MBX Biosciences | MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. | $34.6M | Series A | Jul 27, 2020 |  |
| Passage Bio | Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $110M | Series B | Sep 04, 2019 |  |
| Passage Bio | Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $115.5M | Series A | Feb 15, 2019 |  |
| Recida Therapeutics | Recida Therapeutics is a Biotechnology company. | $8.5M | Series A | Feb 07, 2019 |  |

10 of 16 investments shown.

## Co-investors
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 4 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 3 deals together

## About Frazier Healthcare Partners

VC Fund · Seattle, United States

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations.Frazier’sexperienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.

5 contacts available at Frazier Healthcare Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Nathan Every | General Partner | https://shizune.co/investors/profile/nathan-every |
| Patrick Heron | General Partner | https://shizune.co/investors/profile/patrick-heron |
| Tadataka Yamada | Senior Entrepreneur in Residence | https://shizune.co/investors/profile/tadataka-yamada |
| Alan D. Frazier | Managinig Partner, Founder & Chairman | https://shizune.co/investors/profile/alan-d-frazier |
| Bob Baltera | Entrepreneurs In Residence | https://shizune.co/investors/profile/bob-baltera |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Patrick Heron invest in?

Patrick Heron invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Patrick Heron last invest?

The most recent investment recorded for Patrick Heron closed in Oct 2025. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co